Drug Profile
Research programme:infectious disease therapeutics - Boehringer Ingelheim/Numerate
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim (Canada); Numerate
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Infections in Canada
- 16 Jul 2016 No recent reports of development identified for research development in Infections in USA
- 06 Dec 2011 Early research in Infections in Canada (unspecified route)